Related Experiment Video
Updated: Aug 23, 2026

Standardized Modular Assembly of Polycistronic Operons with Modular Cloning (MoClo) using the In-Cloning toolkit
Published on: September 2, 2025
Myobloc
1Department of Dermatology, University of North Carolina, Chapel Hill, NC 27514, USA. flynn@caryskincenter.com
Abstract:
Myobloc is the currently available commercial formulation of type B botulinum toxin. Released in the United States in 2000, it is approved by the Food and Drug Administration for the treatment of cervical dystonia. The most commonly used botulinum toxins, the type A toxins (Botox and Dysport), affect the SNAP-25 protein, whereas the type B toxin (Myobloc) affects vesicle-associated membrane protein, also known as synaptobrevin. Both type B and type A are antigenically distinct. This article explains the difference between Myobloc and type A toxins, reviews equivalency and other published studies, and describes practical uses for this product in facial aesthetics.
Related Concept Videos
Characteristics and Nomenclature of Homopolymers
Manufacture of Concrete Masonry Units
These wet blocks are then transported for curing, which can occur in one of two environments: a...
Characteristics and Nomenclature of Copolymers
Brick Masonry
For thicker walls, multiple wythes are bonded together using...
A Single-Component System
Stone Masonry

